Mithra Pharmaceuticals SA

ENXTBR:MITRA Rapport sur les actions

Capitalisation boursière : €12.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Mithra Pharmaceuticals Résultats passés

Passé contrôle des critères 0/6

Les bénéfices de Mithra Pharmaceuticals ont diminué à un taux annuel moyen de -23.7%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en à 12.5% par an. Les revenus ont augmenté de en baisse à un taux moyen de 12% par an.

Informations clés

-23.7%

Taux de croissance des bénéfices

31.8%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie12.4%
Taux de croissance des recettes-12.0%
Rendement des fonds propresn/a
Marge nette-432.1%
Prochaine mise à jour des résultats26 Sep 2024

Mises à jour récentes des performances passées

Recent updates

Not Many Are Piling Into Mithra Pharmaceuticals SA (EBR:MITRA) Stock Yet As It Plummets 26%

Apr 06
Not Many Are Piling Into Mithra Pharmaceuticals SA (EBR:MITRA) Stock Yet As It Plummets 26%

Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive

Feb 07
Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive

Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts

Nov 09
Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts

These Analysts Just Made A Huge Downgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) EPS Forecasts

Oct 05
These Analysts Just Made A Huge Downgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) EPS Forecasts

Take Care Before Diving Into The Deep End On Mithra Pharmaceuticals SA (EBR:MITRA)

May 23
Take Care Before Diving Into The Deep End On Mithra Pharmaceuticals SA (EBR:MITRA)

Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts

Aug 11
Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts

Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%

Mar 13
Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%

Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt

Dec 22
Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt

Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Nov 24
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt

Jun 07
Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt

When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?

May 10
When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?

Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?

Mar 18
Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?

We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings

Feb 16
We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings

Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long

Jan 21
Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long

Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Nov 29
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Ventilation des recettes et des dépenses

Comment Mithra Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

ENXTBR:MITRA Recettes, dépenses et bénéfices (EUR Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
31 Dec 2340-1742463
30 Sep 2351-1262166
30 Jun 2363-791769
31 Mar 2365-691766
31 Dec 2267-601764
30 Sep 2244-761670
30 Jun 2222-931676
31 Mar 2222-1051581
31 Dec 2123-1171485
30 Sep 2121-1151586
30 Jun 2119-1131687
31 Mar 2114-1031783
31 Dec 209-921778
30 Sep 2044-311771
30 Jun 2079291664
31 Mar 208811661
31 Dec 1997-271657
30 Sep 1984-541547
30 Jun 1971-821437
31 Mar 1964-551236
31 Dec 1858-281136
30 Sep 1846-411039
30 Jun 1833-531042
31 Mar 1833-461045
31 Dec 1732-381048
30 Sep 1726-371246
30 Jun 1720-361343
31 Mar 1721-361439
31 Dec 1622-351634
30 Sep 1621-291729
30 Jun 1620-231924
31 Mar 1620-161717
31 Dec 1520-10159
30 Sep 1519-9137
30 Jun 1518-8104
31 Mar 1519-5103
31 Dec 1419-3103
31 Dec 1318-281

Des revenus de qualité: MITRA n'est actuellement pas rentable.

Augmentation de la marge bénéficiaire: MITRA n'est actuellement pas rentable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: MITRA n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 23.7% par an.

Accélération de la croissance: Impossible de comparer la croissance des bénéfices de MITRA au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable

Bénéfices par rapport au secteur d'activité: MITRA n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Pharmaceuticals ( 4.5% ).


Rendement des fonds propres

ROE élevé: Le passif MITRA dépasse son actif, il est donc difficile de calculer son rendement des capitaux propres.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé